Role of cytotechnologists in rapid onsite adequacy assessment of cytology materials for diagnostic workup and specimen allocation for ancillary testing using a standardized protocol

Russel Fetzer, Michelle Duey, Valerie Pena, Dana Wanzer, James Kirkpatrick, Donnie Chau, Venetia R Sarode

Research output: Contribution to journalArticle

Abstract

Introduction: Data on the performance of cytotechnologists in assessing specimen adequacy of needle core biopsies (NCB) is scant and their role in specimen triaging for ancillary studies have not been well established. Materials and methods: We retrospectively analyzed rapid onsite evaluation (ROSE) performed exclusively by cytotechnologists on 248 NCB and fine-needle aspiration (FNA) specimens. Overall adequacy and accuracy rates were determined by comparing to final diagnosis. We also reviewed the process of specimen allocation for ancillary testing to determine whether specimens were appropriately triaged at the time of ROSE. Results: Of the 248 cases, 222 (89.5%) were touch imprint and 26 (10.5%) were FNA smears. The overall adequacy rate was 73.4% (182 of 248). Concordance for “adequate” interpretation by ROSE with unequivocal malignant or benign diagnoses on final interpretation was 95.6%. The sensitivity, specificity, and accuracy of ROSE for a final “positive for malignancy” were 89.2% (95% CI 83.04% to 93.69%), 43.24% (95% CI 31.77% to 55.28%), and 73.87% (95% CI 67.57% to 55.28%), respectively. Cases with “positive for malignancy” on final diagnosis were “adequate” by ROSE in 89.1% (132 of 148) and “inadequate” in 10.8% (16 of 148), P < 0.0001. Ancillary tests were performed in 168 of 248 (67.7%); the majority were immunohistochemical stains for determining tumor subtype. Predictive biomarkers were performed successfully in 100% of metastatic breast cancers. Conclusions: Cytotechnologists performed at a high level of competency in providing ROSE and allocating specimens for ancillary testing, which were performed successfully in the majority of cases. Implementation of a standardized protocol for tissue management/prioritization is of paramount importance to maximize tissue preservation and minimize wastage.

Original languageEnglish (US)
JournalJournal of the American Society of Cytopathology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Cell Biology
Large-Core Needle Biopsy
Fine Needle Biopsy
Tissue Preservation
Neoplasms
Touch
Coloring Agents
Biomarkers
Breast Neoplasms
Sensitivity and Specificity

Keywords

  • Ancillary testing
  • Cytotechnologist
  • Rapid on-site evaluation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Role of cytotechnologists in rapid onsite adequacy assessment of cytology materials for diagnostic workup and specimen allocation for ancillary testing using a standardized protocol. / Fetzer, Russel; Duey, Michelle; Pena, Valerie; Wanzer, Dana; Kirkpatrick, James; Chau, Donnie; Sarode, Venetia R.

In: Journal of the American Society of Cytopathology, 01.01.2019.

Research output: Contribution to journalArticle

@article{f2f19fd944414704851376aa33a0d3a7,
title = "Role of cytotechnologists in rapid onsite adequacy assessment of cytology materials for diagnostic workup and specimen allocation for ancillary testing using a standardized protocol",
abstract = "Introduction: Data on the performance of cytotechnologists in assessing specimen adequacy of needle core biopsies (NCB) is scant and their role in specimen triaging for ancillary studies have not been well established. Materials and methods: We retrospectively analyzed rapid onsite evaluation (ROSE) performed exclusively by cytotechnologists on 248 NCB and fine-needle aspiration (FNA) specimens. Overall adequacy and accuracy rates were determined by comparing to final diagnosis. We also reviewed the process of specimen allocation for ancillary testing to determine whether specimens were appropriately triaged at the time of ROSE. Results: Of the 248 cases, 222 (89.5{\%}) were touch imprint and 26 (10.5{\%}) were FNA smears. The overall adequacy rate was 73.4{\%} (182 of 248). Concordance for “adequate” interpretation by ROSE with unequivocal malignant or benign diagnoses on final interpretation was 95.6{\%}. The sensitivity, specificity, and accuracy of ROSE for a final “positive for malignancy” were 89.2{\%} (95{\%} CI 83.04{\%} to 93.69{\%}), 43.24{\%} (95{\%} CI 31.77{\%} to 55.28{\%}), and 73.87{\%} (95{\%} CI 67.57{\%} to 55.28{\%}), respectively. Cases with “positive for malignancy” on final diagnosis were “adequate” by ROSE in 89.1{\%} (132 of 148) and “inadequate” in 10.8{\%} (16 of 148), P < 0.0001. Ancillary tests were performed in 168 of 248 (67.7{\%}); the majority were immunohistochemical stains for determining tumor subtype. Predictive biomarkers were performed successfully in 100{\%} of metastatic breast cancers. Conclusions: Cytotechnologists performed at a high level of competency in providing ROSE and allocating specimens for ancillary testing, which were performed successfully in the majority of cases. Implementation of a standardized protocol for tissue management/prioritization is of paramount importance to maximize tissue preservation and minimize wastage.",
keywords = "Ancillary testing, Cytotechnologist, Rapid on-site evaluation",
author = "Russel Fetzer and Michelle Duey and Valerie Pena and Dana Wanzer and James Kirkpatrick and Donnie Chau and Sarode, {Venetia R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jasc.2019.08.005",
language = "English (US)",
journal = "Journal of the American Society of Cytopathology",
issn = "2213-2945",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Role of cytotechnologists in rapid onsite adequacy assessment of cytology materials for diagnostic workup and specimen allocation for ancillary testing using a standardized protocol

AU - Fetzer, Russel

AU - Duey, Michelle

AU - Pena, Valerie

AU - Wanzer, Dana

AU - Kirkpatrick, James

AU - Chau, Donnie

AU - Sarode, Venetia R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Data on the performance of cytotechnologists in assessing specimen adequacy of needle core biopsies (NCB) is scant and their role in specimen triaging for ancillary studies have not been well established. Materials and methods: We retrospectively analyzed rapid onsite evaluation (ROSE) performed exclusively by cytotechnologists on 248 NCB and fine-needle aspiration (FNA) specimens. Overall adequacy and accuracy rates were determined by comparing to final diagnosis. We also reviewed the process of specimen allocation for ancillary testing to determine whether specimens were appropriately triaged at the time of ROSE. Results: Of the 248 cases, 222 (89.5%) were touch imprint and 26 (10.5%) were FNA smears. The overall adequacy rate was 73.4% (182 of 248). Concordance for “adequate” interpretation by ROSE with unequivocal malignant or benign diagnoses on final interpretation was 95.6%. The sensitivity, specificity, and accuracy of ROSE for a final “positive for malignancy” were 89.2% (95% CI 83.04% to 93.69%), 43.24% (95% CI 31.77% to 55.28%), and 73.87% (95% CI 67.57% to 55.28%), respectively. Cases with “positive for malignancy” on final diagnosis were “adequate” by ROSE in 89.1% (132 of 148) and “inadequate” in 10.8% (16 of 148), P < 0.0001. Ancillary tests were performed in 168 of 248 (67.7%); the majority were immunohistochemical stains for determining tumor subtype. Predictive biomarkers were performed successfully in 100% of metastatic breast cancers. Conclusions: Cytotechnologists performed at a high level of competency in providing ROSE and allocating specimens for ancillary testing, which were performed successfully in the majority of cases. Implementation of a standardized protocol for tissue management/prioritization is of paramount importance to maximize tissue preservation and minimize wastage.

AB - Introduction: Data on the performance of cytotechnologists in assessing specimen adequacy of needle core biopsies (NCB) is scant and their role in specimen triaging for ancillary studies have not been well established. Materials and methods: We retrospectively analyzed rapid onsite evaluation (ROSE) performed exclusively by cytotechnologists on 248 NCB and fine-needle aspiration (FNA) specimens. Overall adequacy and accuracy rates were determined by comparing to final diagnosis. We also reviewed the process of specimen allocation for ancillary testing to determine whether specimens were appropriately triaged at the time of ROSE. Results: Of the 248 cases, 222 (89.5%) were touch imprint and 26 (10.5%) were FNA smears. The overall adequacy rate was 73.4% (182 of 248). Concordance for “adequate” interpretation by ROSE with unequivocal malignant or benign diagnoses on final interpretation was 95.6%. The sensitivity, specificity, and accuracy of ROSE for a final “positive for malignancy” were 89.2% (95% CI 83.04% to 93.69%), 43.24% (95% CI 31.77% to 55.28%), and 73.87% (95% CI 67.57% to 55.28%), respectively. Cases with “positive for malignancy” on final diagnosis were “adequate” by ROSE in 89.1% (132 of 148) and “inadequate” in 10.8% (16 of 148), P < 0.0001. Ancillary tests were performed in 168 of 248 (67.7%); the majority were immunohistochemical stains for determining tumor subtype. Predictive biomarkers were performed successfully in 100% of metastatic breast cancers. Conclusions: Cytotechnologists performed at a high level of competency in providing ROSE and allocating specimens for ancillary testing, which were performed successfully in the majority of cases. Implementation of a standardized protocol for tissue management/prioritization is of paramount importance to maximize tissue preservation and minimize wastage.

KW - Ancillary testing

KW - Cytotechnologist

KW - Rapid on-site evaluation

UR - http://www.scopus.com/inward/record.url?scp=85072300365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072300365&partnerID=8YFLogxK

U2 - 10.1016/j.jasc.2019.08.005

DO - 10.1016/j.jasc.2019.08.005

M3 - Article

JO - Journal of the American Society of Cytopathology

JF - Journal of the American Society of Cytopathology

SN - 2213-2945

ER -